pain.
Conditions
Interventions
Intervention 1: Intervention group 1: will be treated with Nortriptyline 10 mg of Abidi company on a daily basis
which is based on the clinical response of pain reduction (which is based on previous clinical trials a reduction of more than 30% in the baseline VAS score) for patients who did not achieve a clinica
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Confirmation of the clinical diagnosis of mild to moderate Rheumatoid Arthritis by a rheumatologist Presence of RF or AntiCCP in the serum of patients Patients under treatment with methotrexate, prednisolone and hydroxychloroquine Articular involvement without extra-articular involvement Age range from 18 to 70 years Pain complaint Consent to participate in the study
Exclusion criteria
Exclusion criteria: The presence of major psychiatric disorders, including depression, anxiety disorders, bipolar, schizophrenia, abuse of any substance and medication. History of allergy to Duloxetine or Nortriptyline Pregnancy, breastfeeding, or planning to become pregnant in the near future Refusing to consent to receive treatment according to the instructions of this protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain level. Timepoint: Pain measurement before, 1 month, 2 months and 3 months after the start of taking one of the two drugs Nortriptyline and Duloxetine. Method of measurement: Visual Analogue Scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRoya Vaziri Harami
Shahid Beheshti University of Medical Sciences
Outcome results
None listed